pre-IPO PHARMA

COMPANY OVERVIEW

Sound Pharmaceuticals, Inc. (SPI) is developing therapeutics that will enable doctors and patients to prevent and treat various forms of hearing loss. Sensorineural hearing loss is the third largest disease in the industrialized world and affects 50 million Americans. Estimates from the NIH and the CDC place the total annual costs of hearing loss at approximately $50 billion per year in the U.S. alone.


LOCATION

  • Seattle, WA, USA

  • THERAPEUTIC AREAS

  • Neurological Disorders

  • WEBSITE

    https://soundpharma.com/


    CAREER WEBSITE

    https://soundpharma.com/careers-2/


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    May 11, 2022

    Sound Pharmaceuticals' NIH Grant for a novel oral COVID-19 treatment increases to $4.2M


    Apr 6, 2021

    Sound Pharmaceuticals awarded $3.1M NIH grant to test SPI-1005 in COVID-19


    Aug 31, 2020

    FDA allows Sound Pharmaceuticals to test SPI-1005 as a novel treatment for COVID-19


    Jul 30, 2020

    Sound Pharmaceuticals files IND to test SPI-1005 in Phase 2 COVID-19 trials


    May 4, 2020

    University of Oxford and Sound Pharmaceuticals complete Phase 2 Bipolar Disorder Study with SPI-1005


    For More Press Releases


    Google Analytics Alternative